Margaret L. MacMillan

10.8k total citations · 1 hit paper
195 papers, 6.3k citations indexed

About

Margaret L. MacMillan is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Oncology. According to data from OpenAlex, Margaret L. MacMillan has authored 195 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 147 papers in Hematology, 51 papers in Public Health, Environmental and Occupational Health and 47 papers in Oncology. Recurrent topics in Margaret L. MacMillan's work include Hematopoietic Stem Cell Transplantation (134 papers), Acute Lymphoblastic Leukemia research (48 papers) and Acute Myeloid Leukemia Research (37 papers). Margaret L. MacMillan is often cited by papers focused on Hematopoietic Stem Cell Transplantation (134 papers), Acute Lymphoblastic Leukemia research (48 papers) and Acute Myeloid Leukemia Research (37 papers). Margaret L. MacMillan collaborates with scholars based in United States, United Kingdom and Canada. Margaret L. MacMillan's co-authors include Todd E. DeFor, Daniel J. Weisdorf, John E. Wagner, Bruce R. Blazar, Stella M. Davies, Norma K.C. Ramsay, Claudio G. Brunstein, Mukta Arora, Linda J. Burns and Shernan G. Holtan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Scientific Reports.

In The Last Decade

Margaret L. MacMillan

187 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival

2002 743 citations John E. Wagner, Todd E. DeFor et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Margaret L. MacMillan United States	40	4.5k	1.9k	1.5k	1.3k	1.0k	195	6.3k
John Koreth United States	51	5.9k 1.3×	3.6k 1.8×	2.0k 1.4×	1.4k 1.1×	1.3k 1.3×	199	9.3k
Pierre Bordigoni France	50	3.7k 0.8×	2.1k 1.1×	1.9k 1.3×	1.2k 1.0×	1.3k 1.3×	203	8.0k
Hélène Espérou France	36	2.9k 0.6×	1.0k 0.5×	843 0.6×	1.1k 0.8×	925 0.9×	90	4.6k
Donna A. Wall United States	38	2.6k 0.6×	959 0.5×	1.1k 0.7×	1.4k 1.1×	975 1.0×	153	5.8k
Masahiro Tsuchida Japan	34	2.9k 0.7×	944 0.5×	963 0.7×	527 0.4×	1.2k 1.1×	160	4.3k
Pablo Rubinstein United States	25	2.7k 0.6×	1.8k 0.9×	815 0.6×	1.2k 0.9×	403 0.4×	61	4.9k
Pablo Rubinstein United States	26	2.7k 0.6×	1.2k 0.6×	608 0.4×	1.4k 1.1×	363 0.4×	86	4.4k
Gale Rp United States	48	8.5k 1.9×	3.2k 1.7×	2.8k 1.9×	2.2k 1.7×	2.4k 2.4×	173	11.1k
Shimon Slavin Israel	32	2.2k 0.5×	1.5k 0.8×	906 0.6×	479 0.4×	507 0.5×	166	4.3k
Irene Roberts United Kingdom	49	3.7k 0.8×	2.0k 1.0×	964 0.7×	3.3k 2.6×	914 0.9×	190	9.4k

Countries citing papers authored by Margaret L. MacMillan

Since Specialization

Citations

This map shows the geographic impact of Margaret L. MacMillan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret L. MacMillan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret L. MacMillan more than expected).

Fields of papers citing papers by Margaret L. MacMillan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret L. MacMillan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret L. MacMillan. The network helps show where Margaret L. MacMillan may publish in the future.

Co-authorship network of co-authors of Margaret L. MacMillan

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret L. MacMillan. A scholar is included among the top collaborators of Margaret L. MacMillan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret L. MacMillan. Margaret L. MacMillan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shanley, Ryan, et al.. (2024). Treatment-Responsive Acute Graft-versus-Host Disease after Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes. Transplantation and Cellular Therapy. 30(7). 688.e1–688.e9. 1 indexed citations

Jurdi, Najla El, et al.. (2024). Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease. Transplantation and Cellular Therapy. 30(6). 616–625.

Freyçon, Claire, Vincent‐Philippe Lavallée, David Mitchell, et al.. (2024). Pediatric acute promyelocytic leukemia and Fanconi anemia: Case report and literature review. Clinical Genetics. 106(2). 193–198.

Lach, Francis P., Frank X. Donovan, Margaret L. MacMillan, et al.. (2024). FANCA c.3624C>T (p.Ser1208=) is a hypomorphic splice variant associated with delayed onset of Fanconi anemia. Blood Advances. 8(4). 899–908. 2 indexed citations

Gillis, Nancy, Eric Padron, Tao Wang, et al.. (2023). Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry. Transplantation and Cellular Therapy. 29(10). 640.e1–640.e8. 4 indexed citations

Jurdi, Najla El, Shernan G. Holtan, Benjamin Hillmann, et al.. (2023). Pre‐transplant and longitudinal changes in faecal microbiome characteristics are associated with subsequent development of chronic graft‐versus‐host disease. British Journal of Haematology. 203(2). 288–294. 5 indexed citations

Mamo, Tewodros, Darin Sumstad, Todd E. DeFor, et al.. (2023). Harvest Quality, Nucleated Cell Dose and Clinical Outcomes in Bone Marrow Transplantation: A Retrospective Study. Transplantation and Cellular Therapy. 29(10). 638.e1–638.e8. 1 indexed citations

Young, Jo‐Anne H., Najla El Jurdi, Ahmad Rayes, et al.. (2022). Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(8). 509.e1–509.e11. 3 indexed citations

Mamo, Tewodros, Keli L. Hippen, Margaret L. MacMillan, et al.. (2022). Regulatory T cells: A review of manufacturing and clinical utility. Transfusion. 62(4). 904–915. 3 indexed citations

10.

MacMillan, Margaret L., Keli L. Hippen, David H. McKenna, et al.. (2021). First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. Blood Advances. 5(5). 1425–1436. 54 indexed citations

11.

Holtan, Shernan G., Brian C. Betts, Armin Rashidi, et al.. (2019). Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease. JCI Insight. 4(17). 20 indexed citations

12.

Rashidi, Armin, Ryan Shanley, Shernan G. Holtan, et al.. (2018). Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 24(11). 2190–2196. 11 indexed citations

13.

Amin, Khalid, Usman Yaqoob, Byron P. Vaughn, et al.. (2018). Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid. Modern Pathology. 32(4). 560–567. 12 indexed citations

14.

Ebens, Christen L., et al.. (2017). Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation. 24(4). 765–771. 27 indexed citations

15.

Osborn, Mark J., Cara-lin Lonetree, Beau R. Webber, et al.. (2016). CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia. Stem Cells and Development. 25(20). 1591–1603. 26 indexed citations

16.

Petryk, Anna, Lei Zhang, Todd E. DeFor, et al.. (2016). Endocrinopathies, Bone Health, and Insulin Resistance in Patients with Fanconi Anemia after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 22(8). 1487–1492. 15 indexed citations

17.

Brunstein, Claudio G., Jeffrey S. Miller, David H. McKenna, et al.. (2015). Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood. 127(8). 1044–1051. 303 indexed citations

18.

MacMillan, Margaret L., Todd E. DeFor, Jo‐Anne H. Young, et al.. (2015). Alternative donor hematopoietic cell transplantation for Fanconi anemia. Blood. 125(24). 3798–3804. 66 indexed citations

19.

Johnson, L’Aurelle A., Bhaskar Malayappan, Natalia Tretyakova, et al.. (2011). Formation of cyclophosphamide specific DNA adducts in hematological diseases. Pediatric Blood & Cancer. 58(5). 708–714. 33 indexed citations

20.

MacMillan, Margaret L., Daniel J. Weisdorf, John E. Wagner, et al.. (2002). Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biology of Blood and Marrow Transplantation. 8(7). 387–394. 297 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact